Genomic analysis of the Family Pancreatic Cancer Registry, with special attention to the basal phenotype. Screening and validation of biomarkers by liquid biopsy. (Q3152735): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: translated_label) |
(Changed label, description and/or aliases in fr: translated_label) |
||
| label / fr | label / fr | ||
Analyse génomique du registre du cancer pancréatique familial, avec une attention particulière au phénotype basal. Dépistage et validation des biomarqueurs par biopsie liquide. | |||
Revision as of 16:58, 2 December 2021
Project Q3152735 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Genomic analysis of the Family Pancreatic Cancer Registry, with special attention to the basal phenotype. Screening and validation of biomarkers by liquid biopsy. |
Project Q3152735 in Spain |
Statements
56,500.0 Euro
0 references
113,000.0 Euro
0 references
50.0 percent
0 references
1 January 2019
0 references
31 March 2022
0 references
FUNDACION INVESTIGACION BIOMEDICA HOSPITAL RAMON Y CAJAL
0 references
40°25'0.12"N, 3°42'12.89"W
0 references
28079
0 references
En el 2030 el adenocarcinoma de páncreas exocrino (PDAC) será la segunda causa de muerte por cáncer, tras el cáncer de pulmón. El 80-85% de los pacientes son diagnosticados con enfermedad avanzada. La supervivencia a 5 y a 10 años es del 7% y 5%, respectivamente. La detección precoz durante una etapa potencialmente curable puede ser clave para mejorar la supervivencia. En 2009, establecimos el registro nacional de cáncer de páncreas familiar (PANGENFAM)) para identificar y caracterizar a las familias de alto riesgo y ofrecer a los familiares sanos un programa de cribado para la detección precoz. Gracias a la financiación de proyectos anteriores por el ISCIII (PS09/02221, PI12/0135 y PI15/02101) hemos identificado en este contexto mutaciones potencialmente patogénicas, marcadores en biopsia liquida útiles para un diagnóstico temprano y hemos detectado lesiones premalignas en 2 casos de PDAC y un tumor neuroendocrino, actualmente vivos y libres de tumor. Nuestros objetivos son: 1) continuar con el registro de cáncer de páncreas familiar y su biobanco; 2) el análisis de la eficiencia de los programas de cribado en el FPC y otros grupos de riesgo, 3) identificar las características clínicas, biológicas y moleculares del FPC, especialmente del fenotipo basal, algunas de ellas compartidas con tumores basales en otras localizaciones (vejiga, mama, endometrio), 4) contribuir a la clasificación del PDAC en subgrupos biológicos. Pretendemos incrementar la red de hospitales que colaboran con el registro de FPC, identificar y validar nuevos biomarcadores en biopsia líquida, útiles para la detección precoz en poblaciones de alto riesgo que se ha demostrado tan efectiva, caracterizar el fenotipo basal y colaborar en la clasificación de los pacientes con PDAC, para lograr una terapia individualizada, potencialmente más útil. (Spanish)
0 references
In 2030 exocrine pancreatic adenocarcinoma (PDAC) will be the second leading cause of cancer death after lung cancer. 80-85 % of patients are diagnosed with advanced disease. Survival at 5 and 10 years is 7 % and 5 %, respectively. Early detection during a potentially curable stage can be key to improving survival. In 2009, we established the National Register of Family Pancreatic Cancer (PANGENFAM) to identify and characterise high-risk families and provide healthy family members with a screening program for early detection. Thanks to the funding of previous projects by ISCIII (PS09/02221, PI12/0135 and PI15/02101), we have identified in this context potentially pathogenic mutations, markers in liquid biopsy useful for an early diagnosis and we have detected premalignant lesions in 2 cases of PDAC and one neuroendocrine tumor, currently alive and tumor-free. Our objectives are to: 1) continue the registration of family pancreatic cancer and its biobank; 2) analysis of the efficiency of screening programs in CSF and other risk groups, 3) identify the clinical, biological and molecular characteristics of FPC, especially of the basal phenotype, some of them shared with basal tumors in other locations (bladder, breast, endometrium), 4) contribute to the classification of PDAC into biological subgroups. We aim to increase the network of hospitals that collaborate with the FPC registry, identify and validate new biomarkers in liquid biopsy, useful for early detection in high-risk populations that has been proven so effective, characterise the basal phenotype and collaborate in the classification of patients with PDAC, to achieve an individualised therapy, potentially more useful. (English)
12 October 2021
0 references
Madrid
0 references
Identifiers
PI18_01034
0 references